Karyopharm Therapeutics Inc. (KPTI) financial statements (2022 and earlier)

Company profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments229249262328146130176
Cash and cash equivalents19086129118695058
Short-term investments381631332107780117
Restricted cash and investments621 0  
Receivables22138    
Inventory, net of allowances, customer advances and progress billings430    
Inventory430    
Other undisclosed current assets14976222
Total current assets:276277279335148132178
Noncurrent Assets
Operating lease, right-of-use asset8911
Property, plant and equipment2234233
Long-term investments and receivables 2422294534
Long-term investments 2422294534
Restricted cash and investments1111000
Other undisclosed noncurrent assets20      
Total noncurrent assets:3037167324938
TOTAL ASSETS:305313295341180180215
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities71574237271615
Accounts payable2414654
Accrued liabilities69534132211111
Deferred revenue 02
Debt  2    
Deferred rent credit   0
Deferred revenue and credits2200
Other liabilities1110000
Other undisclosed current liabilities22 9   
Total current liabilities:74604647491615
Noncurrent Liabilities
Long-term debt and lease obligation178129123103   
Long-term debt, excluding current maturities169118110103   
Operating lease, liability91113
Liabilities, other than long-term debt  24122
Deferred revenue and credits122
Deferred revenue  2
Deferred rent credit   4
Other undisclosed noncurrent liabilities12462745   
Total noncurrent liabilities:311202199111122
Total liabilities:385263245158511817
Stockholders' equity
Stockholders' equity attributable to parent(80)5150183129162198
Common stock0000000
Additional paid in capital1,0991,120923857625529455
Accumulated other comprehensive income (loss)01(0)(0)(0)(0)(0)
Accumulated deficit(1,179)(1,070)(873)(674)(495)(366)(257)
Total stockholders' equity:(80)5150183129162198
TOTAL LIABILITIES AND EQUITY:305313295341180180215

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues2101084130200
Revenue, net200
Cost of revenue
(Cost of Goods and Services Sold)
 (0)     
Gross profit:2101084130200
Operating expenses(308)(280)(230)(210)(132)(111)(119)
Other undisclosed operating income 0     
Operating loss:(98)(172)(189)(180)(131)(111)(119)
Nonoperating income (expense)(26)(24)(10)2211
Investment income, nonoperating1354211
Interest and debt expense(26)(27)(16)(2)   
Other undisclosed income from continuing operations before equity method investments, income taxes 27162   
Loss from continuing operations before equity method investments, income taxes:(150)(196)(200)(178)(129)(109)(118)
Other undisclosed income from continuing operations before income taxes26      
Loss from continuing operations before income taxes:(124)(196)(200)(178)(129)(109)(118)
Income tax expense(0)(0)(0)(0)(0)(0) 
Net loss available to common stockholders, diluted:(124)(196)(200)(178)(129)(110)(118)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(124)(196)(200)(178)(129)(110)(118)
Comprehensive loss:(124)(196)(200)(178)(129)(110)(118)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)10(0)00(0)
Comprehensive loss, net of tax, attributable to parent:(124)(196)(199)(178)(129)(110)(118)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: